Drug intelligence / Profile preview

[177Lu]Lu-PSMA-137

Development stage: Phase 1
Lead developer: Peking University First Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[177Lu]Lu-PSMA-137 is a radiopharmaceutical designed for targeted therapy, primarily investigated for metastatic castration-resistant prostate cancer (mCRPC). Developed by Peking University First Hospital, this drug utilizes Lutetium-177 ([177Lu]), a beta-emitting radioisotope, conjugated to a ligand that specifically targets Prostate-Specific Membrane Antigen (PSMA). PSMA is a protein highly expressed on the surface of prostate cancer cells. Upon binding to PSMA, [177Lu]Lu-PSMA-137 delivers localized radiation, leading to DNA damage and subsequent death of the cancer cells. It is currently in early-phase clinical development for mCRPC.

Other names: Lutetium (177Lu) PSMA-137177Lu-PSMA-137

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on [177Lu]Lu-PSMA-137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [177Lu]Lu-PSMA-137.

Explore the full profile